Argen-X

Webpage: www.argen-x.com

General description
arGEN-X is a publically traded therapeutic antibody biotechnology company. We have a proprietary SIMPLE AntibodyTM discovery platform that allows us to discover high affinity, high diversity antibody sets covering essentially all epitopes of a given target. arGEN-X combines active immunisation of llamas with Fab phage display to induce and harvest conventional antibody output of the immune response. In addition to the antibody discovery platform arGEN-X has three Fc modulation technologies: PK enhancement through NHance; Abdeg technology for driving autoimmune antibodies into destruction and finally arGEN-X has a licence for the PotelligentTM technology which can significantly enhance antibody dependent cytotoxicity and tumour cell killing activity.

Key research facilities, infrastructures and equipment
760m2 lab space, equipped with two BiaCore 3000 instruments, FACS machine, AKTA Purifier Llama immunisations are performed off-site under supervision of arGEN-X employees or consultants.

Project members  

  • Dr. Hans de Haard
  • Drs. Michael Saunders 

Follow us on

ONCORNET2.0Follow

ONCOgenic GPCR Network of Excellence and Training. An #EU Marie-Curie ITN of 16 Early Stage Researchers studying CXCR4 and ACKR3 #chemokine #GPCRs in cancer

Avatar
AvatarONCORNET2.0@ONCORNET1·
5 Nov

Great way to finish the week off with some #FCS measurements of CXCR4-expressing HEK cells at @UoNLifeSci 🔬 #FluorescenceFriday

Reply on Twitter 1456685143146500096Retweet on Twitter 1456685143146500096Like on Twitter 14566851431465000969Twitter 1456685143146500096
AvatarONCORNET2.0@ONCORNET1·
20 Oct

Hello everyone!
I am Noemi Karsai and I’m the next in our #ESR introduction series. I’m #ESR11 and I’m originally from Hungary, currently doing my PhD at @UoNLifeSci @COMPARE_UoBUoN, UK.

Reply on Twitter 1450838316912455687Retweet on Twitter 14508383169124556873Like on Twitter 145083831691245568715Twitter 1450838316912455687
AvatarONCORNET2.0@ONCORNET1·
8 Jul

The transatlantic ECI GPCR symposium #ECIGPCR is about to start, we are ready!! Thanks to the organizers for their excellent job gathering almost 500 people across the globe! @cyclic_Andreas @NicoleAPerry1 @BenderSci @DesislavaNeshe1

Reply on Twitter 1413138789736730624Retweet on Twitter 14131387897367306242Like on Twitter 141313878973673062415Twitter 1413138789736730624
AvatarONCORNET2.0@ONCORNET1·
29 Jun

My project will be focused on the role of #CXCR4/ACKR3/GRK2 -governed networks in cancer cell migration and metastasis.

Reply on Twitter 1409800354498232323Retweet on Twitter 1409800354498232323Like on Twitter 14098003544982323234Twitter 1409800354498232323
AvatarONCORNET2.0@ONCORNET1·
29 Jun

Hello 🙂
I am here to continue the series in which all #ESRs are presenting themselves. I am Viviana Marolda and I am in my first year of PhD. I am #ESR13, originally from Italy, and currently, I am working as a PhD student in @CBMSO_CSIC_UAM, at Universidad Autonoma de Madrid.

Reply on Twitter 1409799805195411457Retweet on Twitter 14097998051954114571Like on Twitter 140979980519541145711Twitter 1409799805195411457
AvatarONCORNET2.0@ONCORNET1·
14 Jun

Hey twitter!
I am @DehanComez. I am taking over the Oncornet account for a while to start a series of all #ESRs writing about themselves and their projects. I am #ESR5, originally from Turkey and right now I am working as a PhD student in @COMPARE_UoBUoN , @UniofNottingham , UK.

Reply on Twitter 1404396861121863681Retweet on Twitter 14043968611218636814Like on Twitter 140439686112186368137Twitter 1404396861121863681
Retweet on TwitterONCORNET2.0 Retweeted
AvatarDavid Gloriam@David_Gloriam·
28 May

New review on #gpcr structural dynamics out in COSB. Great teamwork with the @JanaSelent group. Thanks to @Lundbeckfonden and @novonordiskfond https://lnkd.in/eyjrA5V

Reply on Twitter 1398230218188496901Retweet on Twitter 13982302181884969012Like on Twitter 139823021818849690113Twitter 1398230218188496901
AvatarONCORNET2.0@ONCORNET1·
28 May

ONCORNET2.0 is the successor to #ONCORNET. You can see some of the work of ESRs from the first ONCORNET in this special issue of @MolPharmJournal from 2019, with reviews on #CXCR4 and #ACKR3 structure and function: https://molpharm.aspetjournals.org/content/96/6

Reply on Twitter 1398237499756003329Retweet on Twitter 13982374997560033291Like on Twitter 13982374997560033293Twitter 1398237499756003329
AvatarONCORNET2.0@ONCORNET1·
28 May

Hi everyone – we’re on Twitter! ONCORNET2.0 is a #MarieCurie ITN of 16 ESRs across Europe studying #chemokine #GPCRs #CXCR4 and #ACKR3 in cancer. Our projects cover molecular dynamics, medchem, #pharmacology through to translational work. Follow us for updates from our ESRs!

Reply on Twitter 1398206898764140544Retweet on Twitter 13982068987641405444Like on Twitter 139820689876414054417Twitter 1398206898764140544
Load More…

Contact details

Please contact us at:
info@oncornet.eu

ONCORNET Coordinator
VU University Amsterdam
The Netherlands

Funded by

Marie Curie Actions

EU Horizon 2020

European Union